Diagnostic Utility of PD-L1 and TP-53 mRNA As Well As microRNAs Expression in Liquid Biopsy of NSCLC Patients – Pilot Study
Introduction The expression of PD-L1 (programed cell death ligand 1) protein on neoplastic cells is a factor qualifying cancer patients for immunotherapy. However, the status of PD-L1 mRNA expression in plasma or serum has not been well studied in cancer patients. TP-53 (Tumor Protein p53) as tumor suppressor affects the expression of many genes, including microRNAs that regulate PD-L1 expression. Purpose of our study was to evaluate usefulness of analysis of PD-L1 mRNA, microRNAs and TP-53 mRNA expression in liquid biopsy in non-invasive diagnosis of non-small cell lung cancer patients (NSCLC).
Material and methods We examined the expression the expression of TP-53 and PD-L1 mRNA as well as seven microRNAs (miR-17, miR-93, miR-142, miR-519, miR-526, miR-34a-5p and miR-34a-3p) in plasma obtained from 80 NSCLC patients and 39 healthy volunteers. We used quantitative PCR preceded by reverse transcription method.
Results We observed PD-L1 mRNA expression only in 6 (7.5%) NSCLC patients. We showed that expression of TP-53 mRNA and each tested microRNAs were significantly higher in healthy person than in NSCLC patients. Based on the Receiver Operating Characteristic (ROC) analysis, we found that TP-53 mRNA and each of examined microRNAs expression were good diagnostic markers for non-invasive diagnosis of NSCLC. We found a significant, negative correlation between TP-53 mRNA and miR-17 (R=-045, p=0.0005) as well as miR-34a-5p (R=-0.32, p=0.04) expression in patients with advanced NSCLC.
Conclusion The decreased expression of TP-53 mRNA may influence the disruption of microRNAs which could be involved in the regulation of PD-L1 expression in NSCLC patients
Figure 1
Figure 2
Figure 3
Figure 4
Posted 13 Jan, 2021
Received 11 Jan, 2021
Received 11 Jan, 2021
Received 11 Jan, 2021
On 10 Jan, 2021
On 10 Jan, 2021
On 10 Jan, 2021
On 10 Jan, 2021
On 10 Jan, 2021
Invitations sent on 08 Jan, 2021
On 08 Jan, 2021
On 08 Jan, 2021
On 08 Jan, 2021
On 04 Jan, 2021
Diagnostic Utility of PD-L1 and TP-53 mRNA As Well As microRNAs Expression in Liquid Biopsy of NSCLC Patients – Pilot Study
Posted 13 Jan, 2021
Received 11 Jan, 2021
Received 11 Jan, 2021
Received 11 Jan, 2021
On 10 Jan, 2021
On 10 Jan, 2021
On 10 Jan, 2021
On 10 Jan, 2021
On 10 Jan, 2021
Invitations sent on 08 Jan, 2021
On 08 Jan, 2021
On 08 Jan, 2021
On 08 Jan, 2021
On 04 Jan, 2021
Introduction The expression of PD-L1 (programed cell death ligand 1) protein on neoplastic cells is a factor qualifying cancer patients for immunotherapy. However, the status of PD-L1 mRNA expression in plasma or serum has not been well studied in cancer patients. TP-53 (Tumor Protein p53) as tumor suppressor affects the expression of many genes, including microRNAs that regulate PD-L1 expression. Purpose of our study was to evaluate usefulness of analysis of PD-L1 mRNA, microRNAs and TP-53 mRNA expression in liquid biopsy in non-invasive diagnosis of non-small cell lung cancer patients (NSCLC).
Material and methods We examined the expression the expression of TP-53 and PD-L1 mRNA as well as seven microRNAs (miR-17, miR-93, miR-142, miR-519, miR-526, miR-34a-5p and miR-34a-3p) in plasma obtained from 80 NSCLC patients and 39 healthy volunteers. We used quantitative PCR preceded by reverse transcription method.
Results We observed PD-L1 mRNA expression only in 6 (7.5%) NSCLC patients. We showed that expression of TP-53 mRNA and each tested microRNAs were significantly higher in healthy person than in NSCLC patients. Based on the Receiver Operating Characteristic (ROC) analysis, we found that TP-53 mRNA and each of examined microRNAs expression were good diagnostic markers for non-invasive diagnosis of NSCLC. We found a significant, negative correlation between TP-53 mRNA and miR-17 (R=-045, p=0.0005) as well as miR-34a-5p (R=-0.32, p=0.04) expression in patients with advanced NSCLC.
Conclusion The decreased expression of TP-53 mRNA may influence the disruption of microRNAs which could be involved in the regulation of PD-L1 expression in NSCLC patients
Figure 1
Figure 2
Figure 3
Figure 4